Scientific engineering customized to accelerate your R&D and diagnostics pipeline.
We serve as the scientific foundation for pharma, biotech, CROs, and reagent manufacturers, delivering advanced analytical assays, regulatory validations, and cell-line authentications that meet international standards.
Your partner for advanced research
and scientific engineering.
Base Científica operates as your partner for advanced scientific engineering projects: we design, optimize and execute complex assays under strict NDA, in our own labs compliant with ANVISA/FDA/ICH.
We serve pharma, next-generation biotech, CROs that need scientific depth, and demanding reagent makers — in Brazil and abroad.
Five fronts. Five specialties.
Each front addresses a specific pipeline pain — from first pre-clinical assay to regulatory validation and biological raw-material authentication.
Pre-Clinical Research
A reference in innovation for pre-clinical assays — everything your study needs in one place.
Validation of Diagnostic & Pharmaceutical Products
Development and validation of diagnostic and pharmaceutical products with absolute regulatory compliance.
Cell Line Authentication
Precision and reliability for safe pre-clinical results — 16+ STR markers analyzed in 10 days.
Base for CROs
Add high-level R&D engineering and ANVISA/FDA infrastructure to your CRO's portfolio — with no fixed costs.
Women's Health
Molecular biology reference lab — HPV, STIs, gynecological health, fetal sexing and genetics, with nationwide logistics.
Cultivating long-term relationships and continuous collaboration.
We collaborate with leading companies and institutions in molecular diagnostics, biotechnology, healthcare and academic research.
What we're thinking about.
Usability Study for In Vitro Diagnostics: Why Analytical Performance Is Not Enough
A usability study shows what analytical performance does not reveal in self-tests and PCR tests. See the difference between formative and summative evaluation and what ANVISA requires.
ANVISA approves oral drug for breast cancer: the role of preclinical research in the ESR1 mutation
ANVISA approved an oral treatment for advanced breast cancer aimed at patients with the ESR1 mutation. The case shows why well-validated biomarkers are increasingly central to the research and development of new treatments.
6 analytical validation mistakes that delay a regulatory submission
Most regulatory submission delays do not come from the product itself, but from the analytical validation that should support it. Six recurring mistakes in pharmaceuticals and IVD, and how to avoid them before the first assay.
Let's design the scope of your next study.
Send a briefing or request a meeting with our specialists — we reply within 24 business hours.